Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis

Author(s): Patoulias Dimitrios*, Doumas Michael, Kotsis Vasilios, Stavropoulos Konstantinos, Imprialos Konstantinos, Zografou Ioanna, Petidis Konstantinos, Bakatselos Spyridon and Karagiannis Asterios

Volume 16, Issue 4, 2020

Page: [313 - 326] Pages: 14

DOI: 10.2174/1573399815666190614141918

Price: $65

Abstract

Background: A few Randomized Controlled Trials (RCTs) have evaluated the use of liraglutide in Type 1 Diabetes (T1D). Through the present systematic review and meta-analysis, we aim at critically appraising and summarizing those RCTs, providing precise effect estimates.

Methods: We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints. This review is reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement.

Results: We included 5 trials with 2,445 randomized participants. Liraglutide provided modest reductions in HbA1c, with liraglutide 1.8 mg producing the greatest decrease (MD = -0.24%, 95% CI -0.32 to -0.16, I2=0%). Significant weight reduction, up to 4.87 kg with liraglutide 1.8 mg was also observed (95% CI -5.31 to -4.43, I2=0%). Decrease in total daily insulin dose, primarily driven by a decrease in bolus insulin requirements, was demonstrated. Liraglutide decreased non-significantly the odds for severe hypoglycemia (OR=0.80, 95% CI 0.57-1.14, I2=0%), while it increased significantly the odds for gastrointestinal adverse events (for nausea, OR=4.70, 95% CI 3.68-6.00, I2=37%, and for vomiting, OR=2.50, 95% CI 1.54-4.72, I2=27%). A significant increase in heart rate was also demonstrated. No association with diabetic ketoacidosis or malignancies was identified.

Conclusion: In patients with T1D, liraglutide might prove be an adjunct to insulin, improving glycemic control, inducing body weight loss and decreasing exogenous insulin requirements and severe hypoglycemia.

Keywords: Liraglutide, type 1 diabetes, glucagon-like peptide-1, glycated hemoglobin, insulin, body weight.

[1]
Diaz-Valencia PA, Bougnères P, Valleron AJ. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health 2015; 15: 255.
[http://dx.doi.org/10.1186/s12889-015-1591-y] [PMID: 25849566]
[2]
Xu G, Liu B, Sun Y, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. BMJ 2018; 362: k1497.
[http://dx.doi.org/10.1136/bmj.k1497] [PMID: 30181166]
[3]
Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014; 311(17): 1778-86.
[http://dx.doi.org/10.1001/jama.2014.3201] [PMID: 24794371]
[4]
Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med 2017; 376(15): 1419-29.
[http://dx.doi.org/10.1056/NEJMoa1610187] [PMID: 28402773]
[5]
Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373(9680): 2027-33.
[http://dx.doi.org/10.1016/S0140-6736(09)60568-7] [PMID: 19481249]
[6]
Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep 2013; 13(6): 795-804.
[http://dx.doi.org/10.1007/s11892-013-0433-5] [PMID: 24072479]
[7]
Weng J, Zhou Z, Guo L, et al. Incidence of type 1 diabetes in China, 2010-13: population based study. BMJ 2018; 360: j5295.
[http://dx.doi.org/10.1136/bmj.j5295] [PMID: 29298776]
[8]
Chamberlain JJ, Kalyani RR, Leal S, et al. Treatment of type 1 diabetes: synopsis of the 2017 american diabetes association standards of medical care in diabetes. Ann Intern Med 2017; 167(7): 493-8.
[http://dx.doi.org/10.7326/M17-1259] [PMID: 28892816]
[9]
Kähler P, Grevstad B, Almdal T, et al. Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ Open 2014; 4(8)e004806
[http://dx.doi.org/10.1136/bmjopen-2014-004806] [PMID: 25138801]
[10]
Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014; 2(2)CD009122
[http://dx.doi.org/10.1002/14651858.CD009122.pub2] [PMID: 24526393]
[11]
Liu C, Wu D, Zheng X, Li P, Li L. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. Diabetes Technol Ther 2015; 17(2): 142-8.
[http://dx.doi.org/10.1089/dia.2014.0190] [PMID: 25369141]
[12]
Shimada A, Shigihara T, Okubo Y, Katsuki T, Yamada Y, Oikawa Y. Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. Diabetes Metab Res Rev 2011; 27(8): 951-3.
[http://dx.doi.org/10.1002/dmrr.1235] [PMID: 22069291]
[13]
Brophy S, Davies H, Mannan S, Brunt H, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 2011; 9(9)CD006165
[http://dx.doi.org/10.1002/14651858.CD006165.pub3] [PMID: 21901702]
[14]
Guo H, Fang C, Huang Y, Pei Y, Chen L, Hu J. The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2016; 121: 184-91.
[http://dx.doi.org/10.1016/j.diabres.2016.08.022] [PMID: 27741478]
[15]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117-28.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[16]
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4): 323-34.
[http://dx.doi.org/10.1056/NEJMoa1515920] [PMID: 27299675]
[17]
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644-57.
[http://dx.doi.org/10.1056/NEJMoa1611925] [PMID: 28605608]
[18]
Yang Y, Pan H, Wang B, Chen S, Zhu H. Efficacy and safety of SGLT2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Chin Med Sci J 2017; 32(1): 22-7.
[http://dx.doi.org/10.24920/J1001-9242.2007.003] [PMID: 28399981]
[19]
Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018; 20(7): 1755-61.
[http://dx.doi.org/10.1111/dom.13260] [PMID: 29451721]
[20]
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696-705.
[http://dx.doi.org/10.1016/S0140-6736(06)69705-5] [PMID: 17098089]
[21]
Girard J. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab 2008; 34(6 Pt 1): 550-9.
[http://dx.doi.org/10.1016/j.diabet.2008.09.001] [PMID: 19036624]
[22]
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311-22.
[http://dx.doi.org/10.1056/NEJMoa1603827] [PMID: 27295427]
[23]
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834-44.
[http://dx.doi.org/10.1056/NEJMoa1607141] [PMID: 27633186]
[24]
Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519-29.
[http://dx.doi.org/10.1016/S0140-6736(18)32261-X] [PMID: 30291013]
[25]
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373(23): 2247-57.
[http://dx.doi.org/10.1056/NEJMoa1509225] [PMID: 26630143]
[26]
Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377(13): 1228-39.
[http://dx.doi.org/10.1056/NEJMoa1612917] [PMID: 28910237]
[27]
Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov 2010; 9(4): 267-8.
[http://dx.doi.org/10.1038/nrd3148] [PMID: 20357801]
[28]
Dejgaard TF, Frandsen CS, Holst JJ, Madsbad S. Liraglutide for treating type 1 diabetes. Expert Opin Biol Ther 2016; 16(4): 579-90.
[http://dx.doi.org/10.1517/14712598.2016.1160050] [PMID: 26926662]
[29]
Mader JK, Jensen L, Ingwersen SH, Christiansen E, Heller S, Pieber TR. Pharmacokinetic properties of liraglutide as adjunct to insulin in subjects with type 1 diabetes mellitus. Clin Pharmacokinet 2016; 55(11): 1457-63.
[http://dx.doi.org/10.1007/s40262-016-0413-4] [PMID: 27282158]
[30]
Crisci I, Aragona M, Politi KS, Daniele G, Del Prato S. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetol 2015; 52(6): 1129-33.
[http://dx.doi.org/10.1007/s00592-015-0800-6] [PMID: 26293127]
[31]
Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract 2013; 19(6): 963-7.
[http://dx.doi.org/10.4158/EP13065.OR] [PMID: 23807520]
[32]
Harrison LB, Mora PF, Clark GO, Lingvay I. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med 2013; 61(1): 40-4.
[http://dx.doi.org/10.2310/JIM.0b013e318279b7d6] [PMID: 23222002]
[33]
Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011; 165(1): 77-84.
[http://dx.doi.org/10.1530/EJE-11-0330] [PMID: 21646283]
[34]
Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011; 34(7): 1463-8.
[http://dx.doi.org/10.2337/dc11-0096] [PMID: 21593296]
[35]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
[http://dx.doi.org/10.1136/bmj.b2535] [PMID: 19622551]
[36]
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS: Peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 2016; 75: 40-6.
[http://dx.doi.org/10.1016/j.jclinepi.2016.01.021] [PMID: 27005575]
[37]
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
[http://dx.doi.org/10.1136/bmj.d5928] [PMID: 22008217]
[38]
Sedgwick P, Marston L. How to read a funnel plot in a meta-analysis. BMJ 2015; 351: h4718.
[http://dx.doi.org/10.1136/bmj.h4718] [PMID: 26377337]
[39]
Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analysesCochrane handbook for systematic reviews of interventions version 510. The Cochrane Collaboration 2011. [Updated March 2011]
[40]
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-58.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[41]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-60.
[http://dx.doi.org/10.1136/bmj.327.7414.557] [PMID: 12958120]
[42]
Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the adjunct one treat-to-target randomized trial. Diabetes Care 2016; 39(10): 1702-10.
[http://dx.doi.org/10.2337/dc16-0691] [PMID: 27506222]
[43]
Ahrén B, Hirsch IB, Pieber TR, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the adjunct two randomized trial. Diabetes Care 2016; 39(10): 1693-701.
[http://dx.doi.org/10.2337/dc16-0690] [PMID: 27493132]
[44]
Kuhadiya ND, Dhindsa S, Ghanim H, et al. Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care 2016; 39(6): 1027-35.
[http://dx.doi.org/10.2337/dc15-1136] [PMID: 27208343]
[45]
Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2016; 4(3): 221-32.
[http://dx.doi.org/10.1016/S2213-8587(15)00436-2] [PMID: 26656289]
[46]
Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study. Diabetes Care 2015; 38(12): 2250-7.
[http://dx.doi.org/10.2337/dc15-1037] [PMID: 26486191]
[47]
Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36(5): 1384-95.
[http://dx.doi.org/10.2337/dc12-2480] [PMID: 23589542]
[48]
International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care 2017; 40(1): 155-7.
[http://dx.doi.org/10.2337/dc16-2215] [PMID: 27872155]
[49]
Wang W, Liu H, Xiao S, Liu S, Li X, Yu P. Effects of insulin plus glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetes Ther 2017; 8(4): 727-38.
[http://dx.doi.org/10.1007/s13300-017-0282-3] [PMID: 28616805]
[50]
Wang W, Gao Y, Chen D, Wang C, Feng X, Ran X. Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract 2017; 129: 213-23.
[http://dx.doi.org/10.1016/j.diabres.2017.05.007] [PMID: 28552612]
[51]
Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 2017; 19(2): 216-27.
[http://dx.doi.org/10.1111/dom.12804] [PMID: 27717195]
[52]
Singh S, Wright EE Jr, Kwan AY, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 2017; 19(2): 228-38.
[http://dx.doi.org/10.1111/dom.12805] [PMID: 27717130]
[53]
Henry RR, Buse JB, Sesti G, et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr Pract 2011; 17(6): 906-13.
[http://dx.doi.org/10.4158/EP.17.6.906] [PMID: 22193143]
[54]
Seufert J, Bailey T, Barkholt Christensen S, Nauck MA. Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials. Diabetes Obes Metab 2016; 18(7): 721-4.
[http://dx.doi.org/10.1111/dom.12623] [PMID: 26679282]
[55]
Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One 2015; 10(6)e0126769
[http://dx.doi.org/10.1371/journal.pone.0126769] [PMID: 26121478]
[56]
Sun F, Chai S, Li L, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res 2015; 2015157201
[http://dx.doi.org/10.1155/2015/157201] [PMID: 25688373]
[57]
Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015; 100(2): 363-70.
[http://dx.doi.org/10.1210/jc.2014-3421] [PMID: 25590213]
[58]
Fujioka K, O’Neil PM, Davies M, et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity (Silver Spring) 2016; 24(11): 2278-88.
[http://dx.doi.org/10.1002/oby.21629] [PMID: 27804269]
[59]
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8(12): 728-42.
[http://dx.doi.org/10.1038/nrendo.2012.140] [PMID: 22945360]
[60]
Adams JM, Pei H, Sandoval DA, et al. Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons. Diabetes 2018; 67(8): 1538-48.
[http://dx.doi.org/10.2337/db17-1385] [PMID: 29776968]
[61]
Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol 2017; 2(12): 890-9.
[http://dx.doi.org/10.1016/S2468-1253(17)30285-6] [PMID: 28958851]
[62]
Dubé MC, D’Amours M, Weisnagel SJ. Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes. Diabetes Obes Metab 2018; 20(1): 178-84.
[http://dx.doi.org/10.1111/dom.13063] [PMID: 28722271]
[63]
Sherr JL, Patel NS, Michaud CI, et al. Pramlintide but not liraglutide suppresses meal-stimulated glucagon responses in type 1 diabetes. Diabetes Care 2016; 39: 1127-34.
[http://dx.doi.org/10.2337/dc16-0089] [PMID: 27208332]
[64]
Abdul-Ghani MA, Williams K, Kanat M, Altuntas Y, DeFronzo RA. Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis. J Endocrinol Invest 2013; 36(3): 168-73.
[PMID: 22522662]
[65]
McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. Diabetes 2010; 59(10): 2333-9.
[http://dx.doi.org/10.2337/db10-0103] [PMID: 20876723]
[66]
Cryer PE. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes 2014; 63(7): 2188-95.
[http://dx.doi.org/10.2337/db14-0059] [PMID: 24962915]
[67]
Fitzpatrick C, Chatterjee S, Seidu S, et al. Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab 2018; 20(9): 2169-78.
[http://dx.doi.org/10.1111/dom.13348] [PMID: 29740922]
[68]
Amione C, Giunti S, Fornengo P, et al. Incidence of prolonged QTc and severe hypoglycemia in type 1 diabetes: the EURODIAB Prospective Complications Study. Acta Diabetol 2017; 54(9): 871-6.
[http://dx.doi.org/10.1007/s00592-017-1018-6] [PMID: 28634852]
[69]
Hanefeld M, Frier BM, Pistrosch F. Hypoglycemia and cardiovascular risk: is there a major link? Diabetes Care 2016; 39(Suppl. 2): S205-9.
[http://dx.doi.org/10.2337/dcS15-3014] [PMID: 27440834]
[70]
Gruden G, Barutta F, Chaturvedi N, et al. Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2012; 35(7): 1598-604.
[http://dx.doi.org/10.2337/dc11-1531] [PMID: 22584135]
[71]
Kilpatrick ES, Rigby AS, Atkin SL, Frier BM. Does severe hypoglycaemia influence microvascular complications in Type 1 diabetes? An analysis of the Diabetes Control and Complications Trial database. Diabet Med 2012; 29(9): 1195-8.
[http://dx.doi.org/10.1111/j.1464-5491.2012.03612.x] [PMID: 22332940]
[72]
Mattishent K, Loke YK. Meta-analysis: Association between hypoglycaemia and serious adverse events in older patients. J Diabetes Complications 2016; 30(5): 811-8.
[http://dx.doi.org/10.1016/j.jdiacomp.2016.03.018] [PMID: 27083445]
[73]
Lavernia F, Kushner P, Trence D, Rice D, Dailey G, Kuritzky L. Recognizing and minimizing hypoglycemia: The need for individualized care. Postgrad Med 2015; 127(8): 801-7.
[http://dx.doi.org/10.1080/00325481.2015.1086628] [PMID: 26359949]
[74]
Siafarikas A, Johnston RJ, Bulsara MK, O’Leary P, Jones TW, Davis EA. Early loss of the glucagon response to hypoglycemia in adolescents with type 1 diabetes. Diabetes Care 2012; 35(8): 1757-62.
[http://dx.doi.org/10.2337/dc11-2010] [PMID: 22699295]
[75]
Sherr J, Xing D, Ruedy KJ, et al. Lack of association between residual insulin production and glucagon response to hypoglycemia in youth with short duration of type 1 diabetes. Diabetes Care 2013; 36(6): 1470-6.
[http://dx.doi.org/10.2337/dc12-1697] [PMID: 23288858]
[76]
Pieber TR, Deller S, Korsatko S, et al. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab 2015; 17(8): 742-50.
[http://dx.doi.org/10.1111/dom.12473] [PMID: 25855340]
[77]
Frandsen CS, Dejgaard TF, Andersen HU, et al. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study. Diabetes Obes Metab 2017; 19(6): 773-82.
[http://dx.doi.org/10.1111/dom.12830] [PMID: 27868372]
[78]
Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; 10(10)CD006423
[http://dx.doi.org/10.1002/14651858.CD006423.pub2] [PMID: 21975753]
[79]
Li Z, Zhang Y, Quan X, et al. Efficacy and acceptability of glycemic control of glucagon-like peptide-1 receptor agonists among type 2 diabetes: a systematic review and network meta-analysis. PLoS One 2016; 11(5)e0154206
[http://dx.doi.org/10.1371/journal.pone.0154206] [PMID: 27158818]
[80]
Quan C, Talley NJ, Jones MP, Howell S, Horowitz M. Gastrointestinal symptoms and glycemic control in diabetes mellitus: a longitudinal population study. Eur J Gastroenterol Hepatol 2008; 20(9): 888-97.
[http://dx.doi.org/10.1097/MEG.0b013e3282f5f734] [PMID: 18794603]
[81]
Garg M, Ghanim H, Kuhadiya ND, et al. Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes. Diabetes Obes Metab 2017; 19(9): 1306-11.
[http://dx.doi.org/10.1111/dom.12944] [PMID: 28304146]
[82]
Meek TH, Dorfman MD, Matsen ME, et al. Evidence that in uncontrolled diabetes, hyperglucagonemia is required for ketosis but not for increased hepatic glucose production or hyperglycemia. Diabetes 2015; 64(7): 2376-87.
[http://dx.doi.org/10.2337/db14-1562] [PMID: 25633417]
[83]
Tanner M. In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis. Ann Intern Med 2016; 165(12): JC64.
[http://dx.doi.org/10.7326/ACPJC-2016-165-12-064] [PMID: 27992920]
[84]
Kumarathurai P, Anholm C, Larsen BS, et al. Effects of liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebo-controlled crossover study. Diabetes Care 2017; 40(1): 117-24.
[http://dx.doi.org/10.2337/dc16-1580] [PMID: 27797930]
[85]
Smits MM, Tonneijck L, Muskiet MH, et al. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. Eur J Endocrinol 2017; 176(1): 77-86.
[http://dx.doi.org/10.1530/EJE-16-0507] [PMID: 27777261]
[86]
Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155(4): 1280-90.
[http://dx.doi.org/10.1210/en.2013-1934] [PMID: 24467746]
[87]
Nakatani Y, Kawabe A, Matsumura M, et al. Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using holter electrocardiography and power spectrum analysis of heart rate variability. Diabetes Care 2016; 39(2): e22-3.
[PMID: 26681718]
[88]
Dejgaard TF, Johansen NB, Frandsen CS, et al. Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes Obes Metab 2017; 19(5): 734-8.
[http://dx.doi.org/10.1111/dom.12841] [PMID: 27935240]
[89]
Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018; 6(2): 105-13.
[http://dx.doi.org/10.1016/S2213-8587(17)30412-6] [PMID: 29221659]
[90]
Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA. Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care 2017; 40(7): 966-72.
[http://dx.doi.org/10.2337/dc16-2747] [PMID: 28476871]
[91]
Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care 2015; 38(6): 1058-66.
[http://dx.doi.org/10.2337/dc13-1210] [PMID: 25504028]
[92]
Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012; 98(2): 271-84.
[http://dx.doi.org/10.1016/j.diabres.2012.09.008] [PMID: 23010561]
[93]
Giorda CB, Sacerdote C, Nada E, Marafetti L, Baldi I, Gnavi R. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine 2015; 48(2): 461-71.
[http://dx.doi.org/10.1007/s12020-014-0386-8] [PMID: 25146552]
[94]
Storgaard H, Cold F, Gluud LL, Vilsbøll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab 2017; 19(6): 906-8.
[http://dx.doi.org/10.1111/dom.12885] [PMID: 28105738]
[95]
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141(1): 150-6.
[http://dx.doi.org/10.1053/j.gastro.2011.02.018] [PMID: 21334333]
[96]
Monami M, Nreu B, Scatena A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab 2017; 19(9): 1233-41.
[http://dx.doi.org/10.1111/dom.12926] [PMID: 28244632]
[97]
Funch D, Gydesen H, Tornøe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab 2014; 16(3): 273-5.
[http://dx.doi.org/10.1111/dom.12230] [PMID: 24199745]
[98]
Zhao H, Wei R, Wang L, et al. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. Am J Physiol Endocrinol Metab 2014; 306(12): E1431-41.
[http://dx.doi.org/10.1152/ajpendo.00017.2014] [PMID: 24801389]
[99]
Zhao H, Wang L, Wei R, et al. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Diabetes Obes Metab 2014; 16(9): 850-60.
[http://dx.doi.org/10.1111/dom.12291] [PMID: 24641303]
[100]
Lu R, Yang J, Wei R, et al. Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. PLoS One 2018; 13(6)e0198938
[http://dx.doi.org/10.1371/journal.pone.0198938] [PMID: 29897998]
[101]
Crespel A, De Boisvilliers F, Gros L, Kervran A. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology 1996; 137(9): 3674-80.
[http://dx.doi.org/10.1210/endo.137.9.8756532] [PMID: 8756532]
[102]
Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151(4): 1473-86.
[http://dx.doi.org/10.1210/en.2009-1272] [PMID: 20203154]
[103]
Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012; 153(3): 1538-47.
[http://dx.doi.org/10.1210/en.2011-1864] [PMID: 22234463]
[104]
Rosol TJ. On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice. Toxicol Pathol 2013; 41(2): 303-9.
[http://dx.doi.org/10.1177/0192623312472402] [PMID: 23471186]
[105]
Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011; 96(3): 853-60.
[http://dx.doi.org/10.1210/jc.2010-2318] [PMID: 21209033]
[106]
Hegedüs L, Sherman SI, Tuttle RM, et al. No evidence of increase in calcitonin concentrations or development of c-cell malignancy in response to liraglutide for up to 5 years in the leader trial. Diabetes Care 2018; 41(3): 620-2.
[http://dx.doi.org/10.2337/dc17-1956] [PMID: 29279300]
[107]
Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the leader randomized trial. Diabetes Care 2018; 41(8): 1663-71.
[http://dx.doi.org/10.2337/dc17-1825] [PMID: 29898902]
[108]
Guo X, Yang Q, Dong J, Liao L, Zhang W, Liu F. Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Clin Drug Investig 2016; 36(6): 433-41.
[http://dx.doi.org/10.1007/s40261-016-0389-8] [PMID: 26979594]

Rights & Permissions Print Cite
Article Metrics
165
4
© 2024 Bentham Science Publishers | Privacy Policy